The core therapeutic areas of use for the polyherbal preparation relate to the established use of its key components for urinary tract support. Herbal combinations with diuretic properties are intended to increase the amount of urine to achieve flushing of the urinary tract as an adjuvant in minor urinary complaints.

---

What Фитолизин Treats: Main Uses and Benefits

The preparation is commonly used across conditions characterized by periods of heightened symptoms (e.g., cystitis and urolithiasis). It is relevant for easing symptoms related to inflammatory or irritative states and those stemming from increased muscular activity (spasm). It is frequently applied during phases when symptoms become more noticeable, often as a supportive adjunct to primary therapy. The preparation is relevant for easing symptoms related to physical discomfort and supports the management of recurrent or episodic manifestations.

The preparation provides support that helps ease the overall symptom burden, which assists with maintaining functional stability and helps promote the natural cleansing of the urinary tract. This provides supportive relief by easing symptoms that interfere with daily functioning, which helps improve day-to-day comfort during symptomatic periods. Furthermore, it supports the management of recurrent manifestations in patients prone to stone formation (metaphylaxis).

---

Quick Fact: Used for managing Urinary Spasms and Discomfort

Who Can and Cannot Use Фитолизин?

This section outlines the population eligibility and restrictions for using Фитолизин as documented in official government regulatory sources, such as the Summary of Product Characteristics (SmPC).

---

Contraindications and Restrictions

Фитолизин is contraindicated (must not be used) in several specific populations and conditions. This absolute prohibition applies to patients with severe kidney failure, severe heart failure, or edema (fluid retention) resulting from cardiac or renal insufficiency. Additionally, use is prohibited in individuals with known hypersensitivity to any component of the preparation.

Population Group	Regulatory Status
Children and Adolescents (Under 18)	Not recommended (Insufficient safety/efficacy data)
Pregnant or Lactating Women	Not recommended (Insufficient safety information)

---

Conditions Requiring Caution

Use of the preparation requires caution and monitoring in patients with certain pre-existing conditions. These restricted populations include those with liver disease, epilepsy, and diabetes mellitus. Patients with diabetes should monitor blood sugar levels, and all restricted populations should use the medicine only under special consideration, as directed by official labeling.

Adults (18 years and older) who do not have any of the listed contraindications or restrictions are the standard eligible population for use.

Interactions with other medicines and products

Official regulatory documentation for Фитолизин primarily structures its interaction profile around potential changes in the activity and clearance of co-administered substances. The preparation's systemic properties may lead to pharmacodynamic enhancement of specific agents. Regulatory information states that Фитолизин may increase the action of the following classes and specific products:

Interaction Type	Documented Interacting Substances
Pharmacodynamic Enhancement	Anticoagulants, NSAIDs, Hypoglycemic Agents, MAO Inhibitors, Lithium Salts

Interactions relating to exposure alteration are also documented. Due to its established diuretic activity, the product may cause the accelerated excretion (faster removal) of other simultaneously administered medicinal products. Conversely, the official labeling states that the preparation may prolong the action of Pentobarbital and Paracetamol.

Regarding supplements, the official documentation notes that the product may decrease the absorption of Beta-Carotene and Alpha-Tocopherol in the small intestine. No combination is formally classified as contraindicated, and no timing-based separation requirements or specific notes on altered interaction severity for patient populations (e.g., hepatic impairment) are included in the official regulatory documents.

Mechanistic Action of Фитолизин

Фитолизин exerts its mechanism through multiple parallel actions involving various phytochemicals. The anti-inflammatory effect occurs via the inhibition of Cyclooxygenase (COX) enzymes, which reduces the synthesis and local concentration of pro-inflammatory prostaglandins. The resulting physiological consequence is a decrease in afferent sensory signaling and vascular permeability within the urinary tract.

The spasmolytic mechanism involves the modulation of ion channels and receptors on the smooth muscle cells of the ureters and bladder. This interaction reduces intrinsic muscle tone and contractility, which produces the physiological outcome of decreased smooth muscle contraction frequency and intensity, promoting luminal patency.

Simultaneously, constituents interact with renal transport mechanisms in the nephron, promoting saluresis (electrolyte excretion) and subsequent osmotic diuresis. This leads to the effect of increased urine volume and electrolyte excretion, contributing to the dilution of urinary solutes and maintaining colloid stability. Furthermore, certain extracts exhibit a direct antimicrobial effect by disrupting bacterial integrity, resulting in the inhibition of bacterial cell proliferation at the site of action.

The administration of Фитолизин follows a standardized protocol specifying the route, mandatory preparation, and course duration. The preparation is administered via the oral route as a suspension and is not intended for direct consumption as a paste.

Administration Scope

The standard adult dose is quantified as one teaspoon of the paste, which is approximately 5 g of the product. This measure is administered 3 to 4 times per day, establishing a frequent, divided daily schedule.

Preparation requirements dictate that the measured dose must be dissolved in about half a cup (125 mL) of warm, boiled water before being consumed. Standard application involves maintaining increased daily fluid intake throughout the administration period, a procedural condition supporting the product’s function.

Usage Constraints

Regarding age-specific use, the product is not recommended for administration to children and adolescents under 18 years of age due to insufficient data. Furthermore, the use is generally limited to a course of 2 to 4 weeks, with any extension of use requiring medical review to ensure appropriate patient monitoring. The final suspension contains a minimal amount of ethanol which is a component of the preparation.

Research evidence / Overview of studies for Фитолизин

Evidence for Use in Chronic and Recurrent Urinary Tract Issues

The supportive role of this preparation has been studied for conditions characterized by fluctuating or episodic manifestations, such as chronic and recurrent cystitis. Researchers have utilized Randomized Controlled Trials (RCTs) and clinical studies to explore how the preparation might fit into a comprehensive management plan. The trials primarily included Adult Women who had experienced repeated or chronic issues with the lower urinary tract.

These studies monitored outcomes related to physical discomfort, patient-reported outcomes describing perceived discomfort, and the rate of recurrence of symptomatic episodes over defined time intervals. Research has primarily examined the preparation as an adjunct—meaning it was used alongside standard medical treatments, such as antibiotics. Findings from these clinical studies reported patterns related to lower recurrence rates when used as an adjunct to standard therapy. The reported data contributes to understanding the preparation's use in the maintenance phase of the condition. Studies monitored changes in laboratory markers and reported how symptoms evolved in the observed populations.

Evidence for Use in Urolithiasis and Prevention of Recurrence

Research examined conditions involving functional limitations associated with kidney or urinary stones (urolithiasis). Studies explored its application in the metaphylaxis (prevention of recurrence) of stone formation and in managing patients after they underwent procedures to break up stones. Clinical studies examined adults of both sexes with a history of stone disease, particularly those presenting with urate-based stones.

The research examined changes in urinary composition, such as increasing the output of urine (diuresis) and changes to urinary pH levels, and studies monitored the prevention of stone recurrence over several months. Findings described patterns related to measured changes in urinary markers when the preparation was used as part of a structured regimen.

What Remains Uncertain About the Research Evidence

The broader evidence landscape highlights several areas where more information is needed. A key limitation is the fact that the preparation is frequently evaluated as a component within a combination therapy—for instance, alongside antibiotics. This limits the ability of research to clearly isolate the specific patterns associated with the preparation alone. Additionally, comparative evidence is lacking against other single-agent or multi-component herbal preparations. The follow-up durations were limited in many core studies, meaning long-term effects are not fully established.

Common questions about Фитолизин (FAQ)

Q: What is Фитолизин primarily used for according to official documents?

According to its traditional classification, Фитолизин is used as an aid for various conditions of the urinary tract. Official product information indicates its use for infections and inflammations, as well as for urinary tract stones, including small deposits or 'kidney sand.' It also notes its use for prophylaxis (prevention) of kidney stones.

Q: Is Фитолизин a prescription-only medicine or available over-the-counter?

The product is typically classified as a non-prescription or over-the-counter (OTC) medicine in the regions where it is registered. This classification is used for non-prescription availability in the markets where it is registered.

Q: What is the full list of active herbal ingredients in the paste?

The active substance is a concentrated aqueous-ethanolic extract from a multi-herbal formula. This includes a blend of nine plants, such as couch grass rhizome, onion hulls, birch leaf, fenugreek seeds, parsley root, goldenrod herb, horsetail herb, lovage root, and bird's-foot trefoil herb.

Q: Does Фитолизин work for all types of urinary tract discomfort?

The preparation is intended for supportive use in urinary tract concerns. Official guidance states that if symptoms worsen, persist, or if severe signs like fever, pain, difficulty urinating, or blood in the urine occur, medical advice is appropriate. This suggests the product is used in a supportive role rather than for managing acute or severe symptoms alone.

Q: Does the medicine help with the passage of existing small stones?

Regulatory indications include its use for urinary tract stones, specifically citing small deposits or 'kidney sand.' This information describes the preparation as providing support for the natural clearance of small deposits.

Q: Are there any official reports of serious side effects associated with Фитолизин?

Official documentation lists potential adverse reactions primarily related to the gastrointestinal system and allergic hypersensitivity, though their frequency is classified as not known. The safety warnings emphasize that if symptoms like fever, pain, or blood in the urine occur, these are signs that require prompt medical evaluation.

Q: Are there any known cross-allergies between the ingredients and common plant pollens?

The product is strictly contraindicated for anyone with known hypersensitivity to any of its components or to plants belonging to the Asteraceae family. Therefore, it is necessary to review the official contraindications concerning plant allergies.

Q: Are there different versions of Фитолизин available (e.g., forte, capsule)?

While the paste for oral suspension is the primary and most recognized form, official registry entries show that the product is also offered in other dosage forms. These registered alternatives include soft gelatine capsules.

Q: Does the product contain sugar or other components relevant for diabetic patients?

The preparation contains the excipients glycerol and wheat starch. Official labeling indicates that due to a potential hypoglycemic effect from the fenugreek component, blood sugar monitoring may be necessary for individuals with diabetes mellitus.

Q: What should a patient do if they miss a day of use?

The patient information leaflet specifies the recommended course of action if a dose is missed. It states that taking a double dose to compensate for a missed one is not recommended.

Q: What is the official regulatory status of Фитолизин in countries outside of its origin?

The product is classified in markets such as the European Union (EU) as a Traditional Herbal Medicinal Product (THMP). This regulatory status acknowledges its established use for specific indications based on its long-term tradition.

Q: Why do patients often describe the taste as very strong or unusual?

The distinct and strong odor and flavor profile of the paste are due to the presence of several aromatic essential oils in its formulation. These oils, which include Peppermint oil, Sage oil, Orange oil, and Pine oil, contribute to the product’s specific taste.

Q: Can individuals with a history of digestive issues, like gastritis, use Фитолизин?

The regulatory safety profile lists common adverse reactions related to the gastrointestinal system, such as nausea, vomiting, and diarrhea. This potential for adverse effects is a factor that is noted in the official safety information.

Q: Does the product come with an official Patient Information Leaflet (PIL)?

Yes, the official labeling confirms that detailed instructions for use, warnings, and precautions are provided to the user. This information is contained within the official Patient Information Leaflet (PIL) enclosed in the package.

How to Store and Dispose of Phytolysin?

The official storage conditions for Phytolysin (Fitolizin) strictly require the product to be kept at a controlled temperature not exceeding 25 C. The medicine must be stored in its original, closed packaging and kept out of the sight and reach of children to comply with safety regulations.

The shelf-life is typically 3 years for the paste and 2 years for the capsules. The product must not be used after the expiration date listed on the label.

Regarding disposal, regulatory instructions state that the medicine must not be discarded (flushed) into wastewater or regular household waste to protect the environment. Users are required to consult a pharmacist or local waste disposal authority for the correct procedure to dispose of unused or expired product.